On December $8,2023,$ The FDA approved the first gene editing therapy to be used in humans. It is intended to cure sickle cell disease, caused by a mutation in the HBB gene that encodes part of hemoglobin. This mutations results in sickle$-$shaped red blood cells with less flexibility that reduce blood flow and oxygen to tissues throughout the body. One reason that Sickle Cell Disease is a good candidate for gene$-$editing therapies is because it is $($pick the best answer$).$

$$ a monogenic disease

a polygenic disease

$$ a hereditary disease

$$ a non$-$hereditary disease